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Elevated  Tricuspid  Regurgitant  Velocity
(TRV) has been related to higher mortality in
adults and to hemolysis, lower oxygen satura-
tion during 6-minute walk test and acute chest
syndrome  (ACS)  in  children  with  sickle  cell
disease  (SCD).  Hydroxyurea  (HU)  has
reduced TRV value in children and adults. We
describe  a  three  year  old  HbSS  child  with
recurrent ACS, hypoperfusion of the left lung,
mild hemolysis and persistent TRV elevation.
TRV  did  not  normalize  after  HU,  despite
improvement  in  clinical  conditions  and  in
baseline  laboratory  parameters  related  to
hemolysis and blood viscosity, but normalized
after bone marrow transplantation (BMT). Our
experience  suggests  that  in  young  patients,
TRV reduction can be a positive concomitant
effect of BMT.
Introduction
Tricuspid  Regurgitant  Velocity  (TRV)  has
become a reliable marker to screen for doppler-
defined pulmonary hypertension (PH) in sick-
le cell disease (SCD).1 Elevated TRV has been
related to higher mortality in adults2 and to
hemolysis, lower oxygen saturation during 6-
minute walk test3 and acute chest syndrome
(ACS)4 in children, even though it’s clinical
relevance, especially in the paediatric age, is
not yet clearly defined. It remains to be deter-
mined whether TRV, and its association with
mortality, reflects true PH or is a biomarker of
disease severity and systemic vasculopathy in
SCD.5 In fact, even if TRV measurement on
echocardiography can be a first tool to screen
for PH in patients with SCD, recent studies
have clearly shown that only a limited number
of patients with TRV elevation have PH as con-
firmed on cardiac catheterization6and that dif-
ferent factors could play a role in leading to
TRV elevation in different subsets of patients.7-8
Moreover, the causes involved in the genesis
of elevated TRV (role of hemolysis and vaso-
occlusive thromboembolic factors) and of PH
in SCD are still under investigation.5,9-10
Clinical  management  of  TRV  elevation  is
also not clear even if Hydroxyurea (HU) has
been demonstrated to lower TRV value in chil-
dren and adults.11-12 The effect of bone marrow
transplantation  (BMT)  on  TRV  value  and
Doppler-defined PH in SCD has not yet been
reported. We describe a three year old HbSS
child  with  recurrent  ACS  -resulting  in  lung
hypoperfusion-, mild hemolysis and TRV eleva-
tion since age two. He did not improve after
HU treatment but 1 year after undergoing BMT
from an HbAA HLA-related sibling, presents no
signs of hemolysis and normal TRV, although
lung damage remained.
Case Report
A 21-months Nigerian male was diagnosed
with HbSS in occasion of the first ACS present-
ing with infiltration in the left lung and pleural
effusion. At 23 and 26 months he experienced
a second and third ACS with infiltration of the
left lobe. Steady state hematological parame-
ters are shown in Table 1, while steady state
Blood Pressure (BP) and SatO2 were above the
90th percentile  and  97-98%,  respectively.
Steady state TRV at 28 months was 2.8 m/sec.
At 30 months he began HU 10 mg/kg, gradu-
ally increased to 30 mg/kg in four months. The
treatment was well tolerated.
At  42  months,  1  year  after  starting  HU,
despite improvement of hematological param-
eters, TRV was still 2.82 m/sec. BP had dropped
to normal values. ECG and cardiac ultrasound
(including Tissue Doppler) at 21, 38 and 43
months were normal. He never presented with
obstructive  sleep  apnea  or  asthma.
Transcranial  Doppler  (TCD)  velocities
remained conditional before HU and after HU
–time  averaged  mean  velocity  of  maximum
blood  flow  (TAMM)  of  185  cm/sec  and  189
cm/sec, respectively.
Having experienced recurrent ACS and per-
sistent high conditional velocities on TCD, due
to availability of an HbAA HLA- matched sibling
he was offered BMT.
As part of the BMT work-up he underwent
lung CT scan showing numerous perihilar strie
dense in the lower left lobe, with increased den-
sity  of  the  parenchyma,  interpreted  as  lung
scars due to the recurrent ACS, and pulmonary
perfusion  scintigraphy  revealing  hypoperfu-
sion of the entire left lung, mainly of the left
lower lobe respectively (Figure 1).
At 47 months he received BMT with the fol-
lowing  conditioning  regimen:  Thiotepa  8
mg/kg/day  (70  mg  x2  times  on  day  -7),
Treosulfan 14 g/m2/day (9.8 gr on day -6, -5 and
-4), Fludarabine 40 mg/m2/day (28 mg on day -
6,-5,-4  e  -3),  antithymocyte  globulin  175
mg/day  (on  day  -4,-3  and  -2).  Polymorpho  -
nucleated leukocytes and platelet engraftment
occurred at day +20 and +22 respectively. No
transplant  related  complications  were
observed.
One year after BMT he presents with 100%
chimerism, no HbS on electrophoresis and is
currently  well,  having  experienced  no  SCD-
related complications. Hematological and bio-
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chemical values are within normal range for
age (Table 1) and TRV dropped to 2.01 m/sec. A
pulmonary perfusion scintigraphy performed 1
year  after  BMT  still  shows  persistence  of
hypoperfusion  of  the  left  lung  (unchanged
from pre-BMT perfusion scintigraphy). 
Discussion
Our case represents, to our knowledge, the
first reported case of a very young SCD child
with TRV elevation that did not reduce after
HU treatment, but normalized after BMT. 
Several factors contribute to the increase in
TRV in SCD children, including increased pul-
monary  flow  volume  (cardiac  output),
increased  left  ventricular  filling  pressures,
increased blood viscosity, and increased pul-
monary vascular resistance.8 SCD children can
also  experience  systemic  hypertension,  left-
sided volume overload, and abnormal diastolic
function, all of which lead to elevated left ven-
tricular filling pressures and secondary eleva-
tion  of  pulmonary  artery  pressures.  Our
patient had surely several of the above men-
tioned factors.
The lack of response of TRV values to HU
has been described in only one older patient
with severe PH11 and HU efficacy in reducing
TRV values is still open. In fact, while some
studies demonstrated the protective effect of
HU on the development of PH in adults12 and
children,11 others  have  not  and  HU-induced
high haemoglobin F levels have, on the con-
trary, been related to higher TRV velocities.13
HU has reversed Doppler-defined PH in SCD
children11 and  adults12 probably  due  to  the
combined reduction of hemolysis and red cell
adhesion, and to the improvement of vascular
function,14 even when the increase in haemo-
globin concentration was modest (from 8.3 to
8.7 g/dL and from 7.52 to 7.98 g/dL).11,12But HU
was  not  effective  in  reducing  TRV  in  our
patient, despite the increase in Hb level (from
7.08 to 8.1 g/dL), the significant increase of
HbF% and the reduction of hematologic param-
eters related to hemolysis (reticulocytes, AST)
and to blood viscosity (platelets, white blood
cells). Additive effect during HU treatment was
normalization of the BP to the 50th percentile,
while  TCD  velocities  remained  conditional
(TAMM  of  185  cm/sec,  189  cm/sec  and  105
cm/sec  before  HU,  after  HU  and  after  BMT
respectively). 
One  year  after  BMT,  all  haematological
parameters and TRV gradually returned to nor-
mal values (2.7, 2.5, 2 m/sec at 3, 8 and 12
months after BMT) while pulmonary scintigra-
phy  remained  impaired,  suggesting  a  non
causative role of in situ thrombosis in generat-
ing high TRV in our patient. In fact, in situ
thrombosis does occur in PH, but seems to rep-
resent a primary aetiology only in a limited
number of cases.15
BMT has reversed both hemolysis and PH in
two cases of Evans Syndrome presenting with
severe clinical manifestations.16 BMT has also
substantially  reduced  cranial  blood  velocity17
and succeeded in stabilizing both cerebral vas-
culopathy  and  lung  function  in  paediatric
patients with SCD.18,19
The  normalization  of  TRV  in  our  patient
after BMT, despite the persistent hypoperfu-
sion of the left lung, might be due to the HbAA
BMT-related  elimination  of  hemolysis  and
inflammation, with a substantial increase in
haemoglobin (from 8.01 to 12.3 g/dL), and to
the improvement of vascular function. In fact,
while  HU  reduces  hemolysis,  reduces  adhe-
sion molecules (on red cells, platelets, WBC
and  vascular  endothelium)  and  seems  to
improve vascular tone14 while displaying con-
troversial  effects  on  inflammation,20 BMT-
especially if a BMT with HbAA donor- elimi-
nates hemolysis and inflammation, improves
rheological  characteristics  and  determines
substantial vascular repair with restoration of
the endothelial lining and maintenance of vas-
cular homeostatis.21
Under the umbrella of Doppler-defined PH
probably fall different subgroup of patients in
which  the  various  pathogenetic  events
(hemolysis,  oxidant  stress,  inflammatory
stress,  chronic  thromboembolism,  in  situ
thrombosis, chronic hypoxemia with activation
of  proliferative  mediators,  parenchymal  and
vascular  injury)  may  be  differently  involved
and  may  require  different  therapeutic
approaches.9,10,22 In very young patients, TRV
elevation  might  express  a  biomarker  of  dis-
ease  severity  and  systemic  vasculopathy5
instead of true PH and only prospective trials
evaluating  pulmonary  vascular  resistance
could aid in clarifying this issue.
Nevertheless,  our  case  shows  that  TRV
reduction  in  young  patients,  having  experi-
enced recurrent ACS with mild hemolysis and
persistent TRV elevation resistant to HU treat-
ment, can be a positive concomitant effect of
BMT. 
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